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ABSTRACT 
 
Deletions within the neurexin 1 gene (NRXN1; 2p16.3) are associated with autism and have also 
been reported in two families with schizophrenia. We examined NRXN1, and the closely related 
NRXN2 and NRXN3 genes, for copy number variants (CNVs) in 2,977 schizophrenia patients and 
33,746 controls from seven European populations (Iceland, Finland, Norway, Germany, The 
Netherlands, Italy and UK) using microarray data. We found 66 deletions and 5 duplications in 
NRXN1, including a de novo deletion: 12 deletions and 2 duplications occurred in schizophrenia 
cases (0.47%) compared to 49 and 3 (0.15%) in controls. There was no common breakpoint and the 
CNVs varied from 18kb to 420kb. No CNVs were found in NRXN2 or NRXN3. We performed a 
Cochran-Mantel-Haenszel exact test to estimate association between all CNVs and schizophrenia 
(P= 0.13; OR=1.73; 95%CI 0.81-3.50). Because the penetrance of NRXN1 CNVs may vary 
according to the level of functional impact on the gene, we next restricted the association analysis to 
CNVs that disrupt exons (0.17% of cases and 0.020% of controls).  These were significantly 
associated with a high odds ratio (P= 0.0027; OR 8.97, 95% CI 1.8-51.9). We conclude that NRXN1 
deletions affecting exons confer risk of schizophrenia.  
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INTRODUCTION 
 Copy number variants (CNVs) are emerging as an important genomic cause of disease, 
particularly autism where large de novo CNVs may account for up to 10% of cases (1-3). These 
CNVs appear to be highly deleterious and may account for the dramatically reduce fecundity in 
autism; in line with autistic individuals, schizophrenics have fewer children on average than the 
general population and risk increases with paternal age (4,5). It also appears that the same CNVs 
can increase susceptibility to more than one psychiatric phenotype (6). Because of this, CNVs are 
also strong candidates for involvement in the aetiology of schizophrenia.  
 The role of CNVs in schizophrenia is less well documented, but there are classical examples 
such as the translocation disrupting the DISC1 gene in a large Scottish pedigree (7) and velo-cardio-
facial syndrome (VCFS), caused by a large deletion at 22q11 which is associated with psychosis in 
about 30% of cases (8). Several recent papers have also indicated that there might be further 
schizophrenia associated CNVs, especially de novo deletions and duplications (9-14).  
Both Kirov et al. (9) and Walsh et al. (11) investigated individuals with schizophrenia in order to 
identify microdeletions and microduplications >100kb potentially associated with the disease. Each 
study found a deletion disrupting the neurexin 1 gene (NRXN1) at 2p16.3 in one family, in a mother 
and two affected siblings, and identical twins concordant for child-onset schizophrenia respectively. 
However neither was able to determine the prevalence, penetrance or odds ratio of these CNVs 
because of their rarity and the small population size examined. CNVs in NRXN1 have also 
previously been implicated in autism and mental retardation (6, 15-19). In the present study, we 
assessed the association of NRXN1 CNVs with schizophrenia as part of a genome-wide scan in a 
sample of 2,977 schizophrenia patients and 33,746 controls from seven European populations 
(Iceland, Finland, Norway, Germany, The Netherlands, Italy and UK) using microarray data.  
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RESULTS 
For the NRXN1 locus on 2p16.3 we limited our search to include the region between Mb 49,90-
51,50 (Human Genome build36), encompassing all exons of NRXN1 and several hundred kilobases 
of the upstream sequence. For comparison, the deletions reported in schizophrenic patients by  
Kirov et al. (11) spans Mb 51,04-51,29 (Genome build36, 250Kb) and the deletion reported by 
Walsh et al. (13) Mb 50,023-50,137 (Genome build 36, 115kb). Similarly we examined the interval 
for deletions or duplications and tested for their enrichment in schizophrenia (see materials and 
methods section, CNV detection subsection). 
We examined the region in 2,977 schizophrenia patients and 33,746 controls from seven 
European populations (Iceland, Finland, Norway, Germany, The Netherlands, Italy and UK) 
(supplementary table 1). We found 61 NRXN1 deletions, including a de novo deletion, and 5 
duplications in the combined sample (figure 1). The CNVs were found throughout the locus, and 
varied in size from 18 Kb to 420 Kb, with no common breakpoint, although some single 
breakpoints may be shared. We found no obvious sequence elements such as low copy repeats 
(LCRs) in the region that could mediate the rearrangements. In contrast there were no deletions or 
duplications found at the NRXN2 (11p13.1) or NRXN3 (14q31.1) loci, which were searched using an 
identical strategy. 
We found 12 deletions and 2 duplications of NRXN1 in cases (0.47%) compared to 49 and 3 
(0.15%) in the controls, all of which encompassed part of the NRNX1 gene or its promoter (figure 
1). The most common deletion was found in 27 samples including one homozygote. One of these 
was schizophrenic, and two had a diagnosis of alcoholism; the remainder were controls 
(supplementary table 2). Haplotype background suggests that all carriers for the common deletion 
derive from a single founder. A further six deletions and one duplication were seen in two, three and 
four samples respectively while 24 deletions and one duplication were only observed once.  
We performed Cochran-Mantel-Haenszel exact test to estimate association between all 
deletions and duplications and schizophrenia. This analysis gave suggestive results, P= 0.13 
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(OR=1.73; 95%CI 0.81-3.50) for all NRXN1 CNVs in schizophrenia versus controls. Because it is 
likely that the pathogenicity and penetrance of CNVs at this locus vary, depending on the functional 
effect they have on the gene, we next restricted the association analysis to those CNVs which 
disrupt exons. We found seven in cases (0.17%) and five in controls (0.020%); these were more 
strongly associated with schizophrenia and had a higher odds ratio (P= 0.0027; OR 8.97, 95% CI 
1.8-51.9). 
 
 Because almost half of the cases (but not controls) with CNVs were from Germany (6/14), 
we analysed haplotypes in the 5’ region of the NRXN1 gene region to see if we could detect 
evidence of a common ancestor for these six CNVs; however there was no evidence for haplotype 
sharing in the region, unlike the haplotype sharing observed for the common small deletion, 
supporting the notion that the majority of CNVs at this locus are not derived from a founder. 
There was no sex difference among carrier subjects; CNVs were found in eight female and 
six male schizophrenia subjects, 31 female and 21 male controls. CNV type, geographic origin, SNP 
boundaries, position (Human genome build 36) size, phenotype and sex are shown in supplementary 
table 2.  In addition to the deletions in patients with schizophrenia and control subjects with no 
known mental illness, there were five further deletions found in the Icelandic population, in a 
subject with autism, three subject with alcohol dependence and one first degree relative of a 
schizophrenia subject who did not participate in this study. These subjects are shown in figure 1 but 
were not included in the statistical analysis.  
The clinical characteristics of the deletion subjects are shown in table 1; there seems to be 
nothing remarkable about these cases. We also tested allelic association for all SNP markers in the 
2p16.3 region studied here, but no marker remained significantly associated at the 5% level after 
correction for number of performed tests (data not shown). 
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 To address the issue of the role of splicing in NRXN1 deletions, we reviewed all 
available genomic data across the NRXN1 locus for evidence of alternative NRXN1 isoforms and 
identified EST and cDNA transcript evidence to support two additional isoforms, which share many 
exons with NRXN1a, which we term NRXN1a-2 and NRXN1 a-3 (figure 3). The NRXN1a-2 
isoform shares exons 6-14 with NRXN1a, but employs alternative first and last exons. These 
alternative exons allow for distinct expression analysis of the NRXN1a-2 isoform, using probe 
1558708_at on the Affymetrix HG-U133_Plus_2.0 GeneChip (supplementary figure 1c). This 
shows very low expression of NRXN1a-2, predominantly in the brain, compared to much higher 
brain specific expression of NRXN1a and NRXN1b (supplementary figures 1a & 1b). The 
NRXN1a-2 isoform has no signal peptide and no transmembrane domain, however it does contain 
Laminin G domains 2-4 and EGF domains 2 and 3 (figure 3). Evidence for the NRXN1a-3 isoform 
is much less conclusive as it shares all exons with exons 4-18 of NRXN1a. 
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DISCUSSION 
 
In the present study, we used 2,977 schizophrenia patients and 33,746 controls, from seven 
European populations, to examine CNVs at the neurexin 1 locus on 2p16.3.  Deletions at this locus 
have previously been associated with autism and mental retardation (6, 15-19), and deletions were 
also found in two families with schizophrenia. In addition we examined the other two known 
neurexin genes, NRXN2 (11p13.1) and NRXN3 (14q31.1) to see if they also harbour potentially 
pathogenic deletions. Kirov et al. (9) screened 93 cases, and found a deletion at 2p16.3 in one 
affected proband, as well as the unaffected mother and an affected sibling. Walsh et al. (11) found a 
different deletion disrupting NRXN1 in identical twins concordant for childhood-onset 
schizophrenia. However because of the small sample size employed it is not possible to determine 
extent of association and the prevalence and odds ratio for disease risk from their data. In our study 
population, we found an excess of CNVs in the NRXN1 gene in schizophrenia, 0.47% of cases 
compared to 0.15% of controls, which did not reach statistical significance. Conditioning on exon 
disrupting deletions or duplications (i.e. those more likely to be pathogenic) the association became 
significant (P= 0.0027; OR 8.97, 95% CI 1.8-51.9) indicating that CNVs in the region may have 
different pathogenicity or penetrance. There were no CNVs detected in the NRXN2 or NRXN3 loci, 
indicating that deletion or duplication of either of these genes is not a significant factor in disease. 
 
De novo versus segregating deletions 
One of the 2p16.3 deletions reported here (autistic subject, supplementary table 2), was also 
found de novo in the Icelandic population (12), and the remaining rare deletions probably occur de 
novo because they do not show any evidence of a founder effect and the boundaries differ between 
individuals. However we cannot be sure of this as in the present study, the majority of cases with 
deletions do not have parents and other relatives available for analysis. In contrast, the smallest 
common deletion appears to be a segregating polymorphism with a single founder. In the Kirov et 
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al. (9) study, the NRXN1 deletion they found was scored as a segregating polymorphism as it was 
present in a mother and son; in the Walsh et al. (11) study it was found in a pair of MZ twins, with 
the parents not tested, so it is unclear if it arose by a de novo event. These deletions may still be 
predominantly de novo as in the cases found by Kirov et al. (9) the deletion in the mother could 
have occurred de novo in a transmission from a grandparent and subsequently been transmitted to 
her offspring; strong negative selection pressure (the reduced fecundity in male schizophrenics) 
would then mean that this deletion is quickly extinguished from the population. Reduced fecundity 
is well established in schizophrenia, and earlier onset (such as appears to occur in many cases with 
large CNVs) is also associated with lower fecundity. Athough this is seen in both males and females, 
it is more pronounced in males (20-22). As Bassett et al. (20) suggest, these epidemiological 
observations are consistent with “a high mutation rate, consistent with unstable mutations, to 
explain the high prevalence of schizophrenia.” 
 
Heterogeneity of deletions and potential impact on the complex splicing of neurexin 
The heterogeneity of the deletions we have identified at the NRXN1 locus also presents 
difficulties when it comes to assessing association with schizophrenia. Caution is needed in 
interpreting these results as the association we found was not significant when all CNVs were 
examined collectively, and required conditioning on exon-disrupting deletions. It is likely that 
pathogenicity of the deletions and duplications at this locus will vary, depending on the functional 
importance of the DNA deleted. Conditioning on exons is the simplest method of addressing this, as 
protein structure and splicing will be affected, and under this test the association between exonic 
deletions and schizophrenia in our sample is highly significant.  
The complexity of neurexin regulation at the level of alternative splicing has already been 
suggested, with six splice sites with perhaps 1000 isoforms (27) and the potential to theoretically 
generate over 2000 isoforms encoding variant extracellular domains (23); . Although the exact 
impact of deletions of the first exons of NRXN1a on alternative splicing is unclear, it is possible 
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that the expression of alternative NRXN1 isoforms may compensate for the loss of the NRXN1a 
transcript. It is interesting that the first exon of NRXN1a-2 seems to be deleted in the small founder 
deletion observed in 24 subjects most of whom were controls. Considering the very low levels of 
expression of NRXN1a-2, and its frequent deletion in controls, we therefore suggest that NRXN1a-
2 may have a very limited biological role in Neurexin signalling. However, activity of the NRXN1a-
2 isoform may become significant against a background of deletion of the other Neurexin isoforms. 
In such circumstances, even low-level dominant negative activity may become biologically relevant. 
As most known Neurexin interactions are extracellular it is unclear if NRXN1a-2 has any function, 
although if it is secreted it may exert a dominant negative effect by competitive binding with 
NRXN1a interactors; alternatively improper cellular localization of NRXN1a-2 may also be 
deleterious.   
Evidence for the NRXN1a-3 isoform is much less conclusive than other isoforms as it shares 
all exons with exons 4-18 of NRXN1a. This excludes the possibility of differentiation of NRXN1a 
and NRXN1a-3 by expression analysis. There is a high level of mammalian conservation before the 
first exon of NRXN1a-3 and there is also EST evidence to support the existence of this isoform 
although, these ESTs cannot be clearly differentiated from NRXN1a transcripts. The putative 
initiation methionine of the NRXN1a-3 isoform correlates with NRXN1a Met321 roughly a third of 
the way into Laminin G domain 2 of the protein (see figure 3). 
The truncated domain of NRXN1a-3 may not be functional as it has lost a critical Ca2+ 
binding residue Asp306, which also mediates interactions with Neurexophilins (24, 25). Loss of 
Neurexophilin interactions may be particularly relevant to schizophrenia pathology, as 
Neurexophilin-3 knockout mice show no anatomical defects, but remarkable functional 
abnormalities in sensory information processing and motor coordination, evident by increased 
startle response, reduced prepulse inhibition, and poor Rotarod performance (26). It is tempting to 
speculate that the disruption of NRXN1/Neurexophilin interactions that are likely to be seen in all 
our observed exonic deletions may explain some of the pathology of schizophrenia. More detailed 
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bioinformatic and functional biology may be able to shed further light on the genotype-phenotype 
and functional consequences of various deletions at this locus.  
 
Haploinsufficieny as a mechanism of pathogenicity 
In addition to the disruption of splicing and the effects of this on the interaction of neurexin 
proteins with protein partners, the association between NRXN1 deletions and schizophrenia could 
also result from haploinsufficiency of the gene. Given that we see a strong association when 
conditioning on disruption of an exon in the two known RefSeq sequences for NRXN1, and the 
most common and smallest deletion of intron only sequence (although the first exon of the novel 
splice variant NRXN1a-2 (figure 3) appears to be deleted) shows a founder effect and is thus not 
likely to be under strong negative selection pressure, it is not likely that all the deletions we found at 
the NRXN1 locus have the same biological effect on disrupting the function of NRXN1, and some 
will probably be neutral variants. Intron-only deletions could of course disrupt splicing or remove 
essential regulatory elements such as splicing enhancers and/or silencers, and the neurexin 1 gene is 
extensively spliced, with more than 2000 potential isoforms (27). In order to provide further 
information on the effects of these deletions it will be necessary to analyse mRNA and protein 
expression, for example using relative allelic expression of non-deleted exons in NRXN1 mRNA to 
demonstrate which deletions result in haploinsufficiency. 
 
Founder effects and the distribution of neurexin 1 deletions in Europe 
There is also a question of how to treat the sample with regard to geographical origin, as 
most of the deletions in cases were from the German population (6/14; 43%) although of course as 
25% of the examined patients were German in origin, this over-representation could have occurred 
by chance. If these deletions are truly recurrent, and depend on a random mechanism involving 
DNA sequences or recombination rates in the region, one would not expect significant geographic 
clustering. Clustering may indicate deletions which are segregating in the population, perhaps from 
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an ancestral founder, or a pre-mutation or polymorphic DNA sequence which increases the 
probability of a de novo event and is more prevalent in one population than others. A haplotype 
analysis that we performed on the German samples with deletions showed no excess sharing of 
alleles around the NRXN1 5’region, which, when combined with the observed heterogeneity of the 
deletions, strongly opposes a founder effect. The most common deletion, which occurred in 29 
subjects, was also the smallest and showed evidence of a single founder. This may be a neutral 
segregating polymorphism which does not significantly affect NRXN1 function and is not relevant to 
risk of schizophrenia. 
 
Penetrance and frequency of neurexin deletions  
Rare NRXN1 deletions have also been reported in the normal population. Pinto et al., (28) 
found an intronic 71kb deletion in a sample of 506 unrelated healthy individuals from Northern 
Germany and 270 HapMap individuals (chr2:50,826,443-50,897,556) which overlaps with some of 
the intronic deletions seen in the present study, and both Redon et al., (29) (chr2:50,643,118-
50,686,339 Build 36) and Wong et al. (30) found similar sized deletions (chr2:50,651,965-
50,714,553) in single control subjects, one of which removes four exons of the gene. These subjects 
have no known neuropsychiatric phenotype, consistent with the notion that although deletions of 
NRXN1 are strongly associated with mental illness they are not necessarily fully penetrant, as seen 
in the data from the present study, and some individuals may be able to compensate for dosage loss, 
for example through a high expressing residual copy of the gene, another modifying locus, or an 
environmental event which results in a gene-by-environment interaction pathway to disease.   
The 2p16.3 deletions we found are moderately rare, occurring at a rate of about 4.7 per 1000 
cases, and, from the control population in the present study, at about 0.15% of live births. This is 
substantially higher than the VCFS deletion, found in about 0.01% of live births (31), making it one 
of the most common gene deletions known. However if we exclude the deletions in NRXN1 which 
do not disrupt exons and are less likely to be pathogenic, the deletion rate is 1.7 per 1000 (0.17%) in 
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the cases compared to 0.020% in the controls, a rate very comparable to VCFS deletions.  
The structural mutations showing association to schizophrenia disrupt the NRXN1 gene, 
rather than deleting or duplicating the entire gene. A generalised study of structural mutations by 
Lupski and Stankiewicz (32) showed that such mutations are much more likely to have biological 
consequences, in our case deletion of exons from the most prevalent NRXN1a isoform, may favour 
the expression of the rarer NRXN1a-2 and NRXN1a-3 isoforms, which may possibly exert a 
dominant negative effect on Neurexin signalling, particularly through Neurexophilins. 
The odds ratio (~10 fold increase in risk) is less than that associated with the VCFS deletion, 
where about 25% of subjects develop psychosis and the odds ratio for the VCFS deletion is about 
30, assuming a population rate of non-VCFS deletion schizophrenia of about 1% (33). It is possible 
that there are many more CNVs in the human genome which can cause schizophrenia, and these 
could make up a significant proportion of genetic risk for the disease which could prove clinically 
useful, for example through genetic testing.  
Potential deletion mechanisms at the NRXN1 locus 
The nature of the loci studied here raises questions about the mechanisms underlying CNV 
events. Many chromosomal rearrangements are not random events, but the result of genome 
architecture that may create inherent instability (34), such as the long low copy repeats (LCRs) 
typical of many other regions where CNVs have been reported. These result in non-allelic 
homologous recombination (NAHR) between the LCRs on opposite flanks of the deleted/duplicated 
segment. However several genomic disorders are associated with rearrangements whose breakpoints 
do not cluster within LCRs, as in the case of NRXN1 deletions. There we see no evidence of LCRs 
flanking the breakpoints, nor do we find common breakpoints or evidence of sequence duplications 
in the region. The LD pattern is particularly unstructured in the 5’ end of the gene and the upstream 
region where we observe the deletions. This may suggest increased recombination rate in the region 
that may be related to the aggregation of deletions at the site, through an unknown mechanism. 
There are suggestions that CNV events are also associated with the presence of processed 
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pseudogenes, the presence of microsatellites, and non-homologous end joining mediated by micro-
homologies (<25bp homology), especially  in subtelomeric regions, or DNA replication-based 
mechanisms, rather than a NAHR mechanism mediated by larger matching repeats (32, 35, 36). 
Similarly to NRXN1, copy number variants in the PLP1 gene do not show common breakpoints. Lee 
et al. (36) examined this locus and uncovered evidence for sequence complexity at some junctions, 
consistent with a DNA replication-based mechanism of CNV formation (replication Fork Stalling 
and Template Switching, FoSTeS). This mechanism might explain the non-recurrent apparently de 
novo deletions with multiple breakpoints seen in NRXN1. To examine this further, we performed 
long range phasing analysis (37) of the single case of autism known to have a de novo NRXN1 
deletion in the Icelandic population. This showed that no recombinations had occurred in the region 
around the de novo deletion (data not shown), providing further evidence against a role for an 
NAHR mechanism in this case. 
Schizophrenia and autism: aetiological overlap? 
The data from our sample of cases and controls provides support for a role for deletions 
within the NRXN1 gene in schizophrenia, and raises the concept that this disorder has shared genetic 
risk factors with autism. If this is indeed the case, it would change the way the distinctions between 
the diseases is formulated, and therefore has profound clinical implications. In support of this are 
previous observations such as the VCFS deletions at 22q11.2, which appear to increase the risk of 
both autism (38) and schizophrenia (33, 39), and data from the present and other studies indicating 
that neurexin deletions are seen in both disorders as well as other behavioural syndromes (9, 11, 15-
19; 40). On the other hand, the concept of diagnostic overlap between the two disorders is 
controversial: while Rzhetsky et al. (42) provides some theoretical support for aetiological overlap, 
evidence from clinical and epidemiological study is less supportive (42,43). In general there have 
been few genetic and epidemiological studies of potential overlap between the disorders, and the 
present and other studies point the way towards more comprehensive evaluation of potential 
diagnostic overlap between these and indeed other psychiatric disorders in the future. 
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MATERIALS AND METHODS 
Samples 
 A total of 2977 affected and 33746 controls from six European populations were 
successfully examined for CNVs at the NRXN1, NRXN2 and NRXN3 loci studied here 
(supplementary table 1); 1435 schizophrenia patients and 28554 control individuals from the 
Iceland, Scotland, Germany, England, Italy and Finland (The SGENE sample; 
http://www.SGENE.eu), 491 affected and 881 controls from Bonn, Germany, 806 cases and 4039 
controls from the Netherlands and 245 cases and 272 controls from Norway. For a full description 
of samples see Supplementary Information. Ethical approval was obtained from the local Ethics 
Committees. All participants gave written informed consent.  
 The SGENE samples were typed on the HumanHap300 BeadArrayTM (Illumina, San Diego, 
USA) at deCODE genetics. The samples from Bonn were typed at Bonn University on 
HumanHap550v3  BeadArrayTM (Illumina, San Diego, USA). The Dutch samples from Utrecht 
University were genotyped at the University of California, Los Angeles, on HumanHap550v3  
BeadArrayTM (Illumina, San Diego, USA). The remaining Dutch samples were genotyped at 
deCODE genetics on HumanHap300 BeadArrayTM (Illumina, San Diego, USA). The Norwegian 
samples were genotyped on Affymetrix GeneChip GenomeWide SNP 6.0 array and analyzed using 
the Affymetrix Power Tools 1.8.0. Samples with Contrast QC below 0.4 were excluded as 
recommended by the manufacturer.  
CNV detection 
 DosageMiner software, developed at deCODE genetics, and QuantiSNP (44; see below for 
description) was used to identify deletions and duplications around the regions reported by Kirov et 
al. (9) and Walsh et al. (11) in all samples except the Norwegian sample, where only QuantiSNP 
was used. DosageMiner, described in detail elsewhere (12), uses the intensities from SNP probes on 
the Illumina microarrays to estimate copy number of genomic regions, and models factors such as 
SNP effect, sample effect and GC-content the in neighbouring region to normalise the intensities. 
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The software then automatically registers SNP loci where intensities fall above or below an 
empirical threshold. We conditioned our search to include only CNVs with 10 or more contiguous 
markers registered as duplicated or deleted by DosageMiner, in order to reduce the level of false 
positive CNVs identified by the software. We then inspected the intensities by eye for all samples 
with a CNV identified by the software. We used SNP genotypes for further confirmation in case of 
deletions by conditioning on homozygosity for all markers within the boundaries of the suspected 
CNV. In some instances, the actual CNV may be shorter than 10 contiguous markers, because the 
boundaries called by DosageMiner may not always be entirely accurate.  
 The QuantiSNP software, developed at the Wellcome Trust Centre for Human Genetics and 
at the University of Oxford (http://www.well.ox.ac.uk/QuantiSNP/), relies on an Objective Bayes 
Hidden-Markov Model to estimate copy number variations (44). In this model, the hidden states 
denote the unknown copy number at the inspected SNPs. Genotype data was used to compute 
different states. Based on the ratio of fluorescent dye ratios (logR) and stretches of homozygosity, 
the algorithm computes a Bayes factor that is used to calibrate the model to a fixed type I (false-
positive) error rate. A Bayes factor threshold of 10 is considered as a promising value for the 
possible presence of a CNV. Usually, such values occur when 5-10 consecutive SNPs are 
deleted/duplicated. Differences in GC base pairs may result in biased hybridization behaviour of 
SNP probes bearing the risk of miscalling genotypes. To normalize for this, QuantiSNP assigns a 
locus-specific GC value to each probe. Again, all potential CNVs detected were subsequently 
visually inspected and confirmed using the BeadStudio software (Illumina, San Diego, USA). We 
used the Cochran-Mantel-Haenszel exact test for the association analysis, which includes a 
correction for population of origin in the analysis. In order to condition on exons, we scored a CNV 
as exon-disruption if it overlapped any known exonic sequence in NRXN1, based on reviewed 
sequence from Human mRNA from RefSeq (NM_004801 for NRXN1-alpha). Long-range phasing 
analysis to detect recombination events in the Icelandic case of autism with a de novo NRXN1 
deletion was performed using the method of Kong et al. (37).  
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LEGENDS TO FIGURE 
 
Figure 1:  
 
UCSC browser output showing the positions of the 2p16.3 CNVs from the Kirov et al., (2008), Walsh et al., (2008), 
Friedman et al., 2008 and Szatzmar et al., 2008 studies (blue lines) relative to the NRXN1 gene, and the CNVs 
discovered in the present study (schizophrenia, red lines; other psychiatric diagnoses, brown lines; controls, green lines). 
The majority of the discovered CNVs are deletions, asterisks indicate duplications. Markers from the Illumina 300K and 
550K arrays, segmental duplications of >1000 bp as well as LD structure of the Hapmap CEU sample (r2) is also shown. 
 
Figure 2: 
UCSC browser output showing the positions of exon-disrupting CNVs discovered in the study relative to the 2p16.3 
CNVs from the Kirov et al., (2008), Walsh et al., (2008), Friedman et al., 2008 and Szatzmar et al., 2008 studies and 
known (schizophrenia, red lines; other psychiatric diagnoses, brown lines; controls, green lines; previously described 
CNVs, blue lines). The four putative Neurexin isoforms are shown below the deletions, along with protein domains 
aligned to genomic sequence. 
 
Figure 3:  
Protein domain organisation of Neurexin 1 isoforms.  NRXN1a contains an N-terminal signal peptide, six laminin G 
(LamG) domains, three epidermal growth factor-like (EGF) domains, a transmembrane domain and a short cytoplasmic 
domain. NRXN1b contains a different signal peptide, but shares the last LamG domain, transmembrane domain and 
cytoplasmic domain with NRXN1a. NRXN1a-2 shares the 2nd, 3rd, 4th and 5th LamG domains and the 2nd and 3rd EGF 
domains with NRXN1a, but does not contain a signal peptide or transmembrane domain. NRXN1a-3 has no signal 
peptide and has a truncated version of the 2nd LamG domain but shares all remaining domains with NRXN1a. The five 
regions in the NRXN1 gene where alternative splicing occurs, leading to insertion or deletion of amino acids is indicated 
by arrows (SS#1-5).  Protein domain annotation was generated using SMART (http://smart.embl-heidelberg.de/), using 
swissprot accessions Q9ULB1 (NRXN1a) and P58400 (NRXN1b) and translations from the genbank transcript 
AK093260 (NRXN1a-2) and Ensembl transcript ENST00000331040 (NRXN1a-3). 
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Table 1 Phenotypic features of schizophrenia cases with 2p deletions.  
 
 Centre  Diagnosis 
 Family history  
of schizophrenia  CNV boundaries 
 Age at 
onset Sex  Other 
Munich 1 DSMIV:295.3 no 
chr2:50,856,110-
50,900,862 27 F. . 
Munich 21 DSMIV:295.3 no 
chr2:50,890,216-
51,116,653 25 M 
Social contact problems in 
childhood 
Munich 3 DSMIV:295.3 no 
chr2:51,147,600-
51,225,851 31 F . 
Verona 11, 2 ICD10: F20.3 
Brother with mental 
illness (not specified) 
chr2:50,071,499-
50,208,992 36 F 
Chronic, positive symptoms, 
low IQ (82), low educational 
level 
Verona 2 ICD10: F20.3 
Yes other psychiatric 
disorder 
chr2:50,822,312-
50,948,557 14 F 
Chronic, negative symptoms, 
episode of aggression 
Helsinki 11 DSMIV:295.3 
Yes, other psychiatric 
disorder 
chr2:51,101,161-
51,344,213 37 M Alcoholism 
Utrecht 1 DSMIV:295.3 
Probably psychosis in first 
or second degree relative 
chr2:50,735,657-
50,800,548 29 F Not mentioned 
Utrecht 22 DSMIV:295.9 Not examined 
chr2:50,786,446-
50,900,862  19 M Not mentioned 
Utrecht 31 DSMIV:295.3  
chr2:51,002,576-
51,250,922 . M . 
Utrecht 41 DSMIV:295.9 None 
chr2:51,0249,62-
51,251,873 Unknown F 
Episodic with partial 
remission and negative 
symptoms 
Reykjavik 1 RDC:126.4 None 
chr2:51,211,406-
51,299,436 26 M Not mentioned 
Bonn 11 DSMIV:295.3 None 
chr2:50,711,199-
50,756,435 18 M 
Myoclonic seizures in the 
right shoulder 
Bonn 2 DSMIV:295.3 None 
chr2:50,836,690-
50,936,258 21 F 
Resistncy in left lower 
abdomen with otherwise 
unremarkable finding 
Bonn 31 DSMIV:295.3 Yes 
chr2:50,850,456-
51,225,851 27 F 
Mental retardation (mild), 
Tardive dyskinesia. 
 
1exon disrupting 
2duplication 
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30 
ABBREVIATIONS 
CI  Confidence interval 
CNV  Copy number variant 
DISC1  Disrupted in schizophrenia 1 
LCRs  low copy repeats 
LD  linkage disequilibrium 
NAHR  non-allelic homologous recombination 
NRXN1 Neurexin 1 
NRXN2 Neurexin 2 
NRXN3 Neurexin 3 
OR  Odds ratio 
VCFS  velo-cardio-facial syndrome 
 
